hallucinations; paranoia; depression; anxiety; apathy; rapid or unprovoked changes in mood; and other neurological or psychological symptoms, where impairment is determined with comparison to baseline ability or level of the neurological or psychological activity or symptom (e.g., before onset of HD symptoms, or upon initial diagnosis of HD symptoms).

**[0008a]** In one aspect, there is provided the use of a heteroaryl ketone fused azadecalin glucocorticoid receptor modulator (GRM) or an octahydro fused azadecalin GRM, in the manufacture of a medicament for treating Huntington's Disease (HD).

**[0008b]** In another aspect, there is provided the use of a pharmaceutical composition in the manufacture of a medicament for treating Huntington's Disease (HD) or a symptom thereof comprising a pharmaceutically acceptable excipient and a nonsteroidal glucocorticoid receptor modulator (GRM) compound comprising a heteroaryl ketone fused azadecalin structure having the formula:




wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, N-oxide, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl;

ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1\ 6}$ haloalkyl, $C_{1\ 6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and

$C_{3-8}$ heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 $R^{2c}$ groups;

alternatively, two $R^2$ groups linked to the same carbon are combined to form an oxo group (=O);

alternatively, two $R^2$ groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2d}$ groups;

$R^{2a}$ and $R^{2b}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{2c}$ is independently selected from the group consisting of hydrogen, halogen, hydroxy, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, and $NR^{2a}R^{2b}$;

each $R^{2d}$ is independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl, or two $R^{2d}$ groups attached to the same ring atom are combined to form (=O);

$R^3$ is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 $R^{3a}$ groups;

each $R^{3a}$ is independently selected from the group consisting of hydrogen, halogen, and $C_{1-6}$ haloalkyl; and

subscript n is an integer from 0 to 3;

or salts and isomers thereof.

**[0008c]** In another aspect, there is provided the use of pharmaceutical composition in the manufacture of a medicament for treating Huntington's Disease (HD) or a symptom thereof comprising a pharmaceutically acceptable excipient and a nonsteroidal glucocorticoid receptor modulator (GRM) compound comprising an octahydro fused azadecalin structure having the formula:




, wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, N-oxide, and $C_{3-8}$ cycloalkyl; ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;

alternatively, two $R^2$ groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2c}$ groups;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{3a}$ is independently halogen; and subscript n is an integer from 0 to 3,

or salts and isomers thereof.

**[0008d]** In another aspect, there is provided the use of a heteroaryl ketone fused azadecalin GRM or an octahydro fused azadecalin GRM in the manufacture of a medicament for treating HD or a symptom thereof.

**[0009]** In examples, the GRM is a selective GRM (SGRM) active at GR but with little or no activity at other steroid hormone receptors (e.g., little or no PR or AR activity). In examples, the GRM is a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure, wherein the heteroaryl ketone fused azadecalin

structure is as described and disclosed in U.S. Patent 8,859,774. In examples, the GRM is a nonsteroidal compound comprising an octahydro fused azadecalin structure, wherein the octahydro fused azadecalin structure is as described and disclosed in U.S. Patent 10,047,082.

**[0010]** In examples, the GRM is the compound comprising a heteroaryl ketone fused azadecalin structure (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo P,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone (termed "dazucorilant" or "CORT113176"), which has the following structure:



.

**[0011]** In examples, the GRM is the compound comprising an octahydro fused azadecalin structure ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone (termed zavacorilant, or "CORT125329"), which has the following structure:



. The entire contents of U.S. Patent 8,859,774 and of U.S. Patent 10,047,082 are hereby incorporated by reference in their entireties.

**[0012]** In examples, the GRM is administered orally to the patient. GRM treatment for HD, or for HD symptoms, may include daily administration of the GRM (e.g., once per day, or twice per day, or other daily schedule of administration); or may include intermittent GRM administration (e.g., once every other day, or once every three days, or twice per week, or other schedule of administration). In examples, the effective amount of the GRM is a dose of between about 1 and about 100 milligrams per kilogram (mg/kg). For example, a GRM dose for daily GRM administration to treat HD, or to treat symptoms of HD, is a dose of between about 1 and about 100 milligrams per kilogram per day (mg/kg/day), or between about 3 mg/kg/day to about 75 mg/kg/day, or between about 5 mg/kg/day to about 50 mg/kg/day. In examples, the daily dose of the GRM is between about 5 milligrams per day (mg/day) and about 3000 mg/day, or between about 10 mg/day and about 2500 mg/day, or between about 20 mg/day and about 2250 mg/day, or between about 30 mg/day and about 2000 mg/day, or between about 40 mg/day and about 1750 mg/day, about 50 mg/day and about 1500 mg/day, or between about 75 mg/day and about 1000 mg/day, or between about 100 mg/day to about 750 mg/day, or between about 150 mg/day to about 500 mg/day. GRM treatment may be administered for as long as needed; thus, such treatment may be for a period of one year, or for a period of several years, or may be administered many years. In examples, GRM treatment comprises GRM administration for at least 1 to about 80 weeks, or more. The GRM may be administered along with other medications or treatments administered to the patient suffering from HD, or during a period of time in which the patient suffering from HD is receiving other medication or treatment for HD or its symptoms.

**[0013]** The present methods provide improved methods of treating HD and for treating symptoms of HD.

## WHAT IS CLAIMED IS:

1. Use of a heteroaryl ketone fused azadecalin glucocorticoid receptor modulator (GRM) or an octahydro fused azadecalin GRM, in the manufacture of a medicament for treating Huntington's Disease (HD).

2. The use of claim 1, wherein the GRM is a heteroaryl ketone fused azadecalin GRM.

3. The use of claim 1, wherein the GRM is an octahydro fused azadecalin GRM.

4. The use of claim 1, wherein the treatment is effective to treat a symptom of HD.

5. The use of claim 4, wherein said symptom of HD is a motor symptom of HD.

6. The use of claim 4, wherein said symptom of HD is a neurological or psychological symptom of HD.

7. The use of claim 5, wherein the motor symptom of HD is a symptom selected from the group of motor symptoms consisting of: involuntary jerking motions (spasms); involuntary writhing motions (chorea); muscular contractions or rigidity (dystonia); tremor; slowed or unusual eye movements; impaired muscle strength; impaired grasp; impaired gait (i.e., difficulty walking); impaired balance; impaired swallowing; impaired respiration; impaired posture; impaired ability to stand upright; impaired ability to maintain head position; and impaired speech,

where impairment is determined with comparison to baseline ability to perform the motor activity (e.g., before onset of HD symptoms, or upon initial diagnosis of HD symptoms),

wherein said administration of an effective amount of said heteroaryl ketone fused azadecalin GRM or of said octahydro fused azadecalin GRM is effective to treat said motor symptom of HD.

8. The use of claim 6, wherein the symptom of HD comprises epileptic seizures, and the treatment is effective to reduce the frequency of said epileptic seizures.

9. The use of claim 6, wherein the symptom of HD comprises epileptic seizures, and the treatment is effective to reduce the frequency or severity of said epileptic seizures.

10. The use of claim 6, wherein the symptom of HD is a neurological or psychological symptom selected from the group of neurological symptoms consisting of: amnesia; other memory loss; mental confusion; impaired speech; impaired ability to concentrate; impaired speed of comprehension; delirium; hallucinations; paranoia; depression; anxiety; apathy; and rapid or unprovoked changes in mood,

where impairment is determined with comparison to baseline ability or level of the neurological or psychological activity or symptom (e.g., before onset of HD symptoms, or upon initial diagnosis of HD symptoms),

wherein said administration of an effective amount of a heteroaryl ketone fused azadecalin GRM or of said octahydro fused azadecalin GRM is effective to treat said neurological or psychological symptom of HD.

11. The use of any of claims 1 to 10, wherein the GRM is a heteroaryl ketone fused azadecalin GRM, and said GRM comprises a chemical structure having the formula:




wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, N-oxide, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl;

ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and

heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1\ 6}$ haloalkyl, $C_{1\ 6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 $R^{2c}$ groups;

alternatively, two $R^2$ groups linked to the same carbon are combined to form an oxo group (=O);

alternatively, two $R^2$ groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2d}$ groups;

$R^{2a}$ and $R^{2b}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{2c}$ is independently selected from the group consisting of hydrogen, halogen, hydroxy, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, and $NR^{2a}R^{2b}$;

each $R^{2d}$ is independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl, or two $R^{2d}$ groups attached to the same ring atom are combined to form (=O);

$R^3$ is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 $R^{3a}$ groups;

each $R^{3a}$ is independently selected from the group consisting of hydrogen, halogen, and $C_{1-6}$ haloalkyl; and

subscript n is an integer from 0 to 3;

or salts and isomers thereof.

12. The use of claim 11, wherein the heteroaryl ketone fused azadecalin GRM is dazucorilant (which is (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo P,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone), which has the following structure:



.

13. The use of any of claims 1 to 10, wherein the GRM is an octahydro fused azadecalin GRM, and said GRM comprises a chemical structure having the formula:



, wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, N-oxide, and $C_{3-8}$ cycloalkyl; ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;

alternatively, two $R^2$ groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2c}$ groups;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{3a}$ is independently halogen; and subscript n is an integer from 0 to 3, or salts and isomers thereof.

14. The use of claim 13, wherein said octahydro fused azadecalin GRM is zavacorilant (which is ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone), which has the following structure:  .

15. Use of a pharmaceutical composition in the manufacture of a medicament for treating Huntington's Disease (HD) or a symptom thereof comprising a pharmaceutically acceptable excipient and a nonsteroidal glucocorticoid receptor modulator (GRM) compound comprising a heteroaryl ketone fused azadecalin structure having the formula:



wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, N-oxide, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl;

ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1\ 6}$ haloalkyl, $C_{1\ 6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 $R^{2c}$ groups;

alternatively, two $R^2$ groups linked to the same carbon are combined to form an oxo group (=O);

alternatively, two $R^2$ groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2d}$ groups;

$R^{2a}$ and $R^{2b}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{2c}$ is independently selected from the group consisting of hydrogen, halogen, hydroxy, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, and $NR^{2a}R^{2b}$;

each $R^{2d}$ is independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl, or two $R^{2d}$ groups attached to the same ring atom are combined to form (=O);

$R^3$ is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 $R^{3a}$ groups;

each $R^{3a}$ is independently selected from the group consisting of hydrogen, halogen, and $C_{1-6}$ haloalkyl; and

subscript n is an integer from 0 to 3;

or salts and isomers thereof.

16. The use of claim 15, wherein the nonsteroidal GRM compound comprising a heteroaryl ketone fused azadecalin structure is dazucorilant (which is (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo P,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone), which has the following structure:



.

17. Use of a pharmaceutical composition in the manufacture of a medicament for treating Huntington's Disease (HD) or a symptom thereof comprising a pharmaceutically acceptable excipient and a nonsteroidal glucocorticoid receptor modulator (GRM) compound comprising an octahydro fused azadecalin structure having the formula:



, wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, N-oxide, and $C_{3-8}$ cycloalkyl; ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;

alternatively, two $R^2$ groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each

independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2c}$ groups;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{3a}$ is independently halogen; and subscript n is an integer from 0 to 3,

or salts and isomers thereof.

18. The use of claim 17, wherein the nonsteroidal GRM compound comprising an octahydro fused azadecalin GRM is zavacorilant (which is ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone), which has the following structure:  .

19. The use of claim 15, for treating a symptom of HD, wherein said symptom of HD is a motor symptom of HD.

20. The use of claim 15, for treating a symptom of HD, wherein said symptom of HD is a neurological or psychological symptom of HD.

21. The use of claim 17, for treating a symptom of HD, wherein said symptom of HD is a motor symptom of HD.

22. The use of claim 17, for treating a symptom of HD, wherein said symptom of HD is a neurological or psychological symptom of HD.

23. Use of a heteroaryl ketone fused azadecalin GRM or an octahydro fused azadecalin GRM in the manufacture of a medicament for treating HD or a symptom thereof.

24. The use of claim 23, wherein said treatment of HD comprises a symptom of HD to be treated.

25. The use of any of claims 23 and 24, wherein said treatment of HD comprises increased cortisol level in a patient suffering from HD to be treated.

26. The use of any of claims 23 and 24, wherein said treatment of HD comprises a motor symptom of HD to be treated.

27. The use of any of claims 23 and 24, wherein said treatment of HD comprises a neurological or psychological symptom of HD to be treated.

28. The use of any of claims 23 and 24, wherein said treatment of HD comprises a motor symptom of HD to be treated, wherein the motor symptom is selected from the group consisting of: involuntary jerking motions (spasms); involuntary writhing motions (chorea); muscular contractions or rigidity (dystonia); tremor; slowed or unusual eye movements; impaired muscle strength; impaired grasp; impaired gait (i.e., difficulty walking); impaired balance; impaired swallowing; impaired respiration; impaired posture; impaired ability to stand upright; impaired ability to maintain head position; and impaired speech.

29. The use of any of claims 23 and 24, wherein said treatment of HD comprises epileptic seizures to be treated.

30. The use of any of claims 23 and 24, wherein said treatment of HD comprises a neurological or psychological symptom of HD to be treated, wherein the neurological or psychological symptom is selected from the group consisting of: amnesia; other memory loss; mental confusion; impaired speech; impaired ability to concentrate; impaired speed of comprehension; delirium; hallucinations; paranoia; depression; anxiety; apathy; and rapid or unprovoked changes in mood.

31. The use of any of claims 23 to 30, wherein the GRM is a heteroaryl ketone fused azadecalin GRM comprising a chemical structure having the formula:




wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, N-oxide, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl;

ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1\ 6}$ haloalkyl, $C_{1\ 6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 $R^{2c}$ groups;

alternatively, two $R^2$ groups linked to the same carbon are combined to form an oxo group (=O);

alternatively, two $R^2$ groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2d}$ groups;

$R^{2a}$ and $R^{2b}$ are each independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl;

each $R^{2c}$ is independently selected from the group consisting of hydrogen, halogen, hydroxy, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, CN, and $NR^{2a}R^{2b}$;

each $R^{2d}$ is independently selected from the group consisting of hydrogen and $C_{1-6}$ alkyl, or two $R^{2d}$ groups attached to the same ring atom are combined to form (=O);

$R^3$ is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 $R^{3a}$ groups;

each $R^{3a}$ is independently selected from the group consisting of hydrogen, halogen, and $C_{1-6}$ haloalkyl; and

subscript n is an integer from 0 to 3;

or salts and isomers thereof.

32. The use of claim 31, wherein the heteroaryl ketone fused azadecalin GRM is dazucorilant (which is (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo P,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone), which has the following structure:



.

33. The use of any of claims 23 to 30, wherein the GRM is an octahydro fused azadecalin GRM comprising a chemical structure having the formula:



, wherein

$R^1$ is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from $R^{1a}$;

each $R^{1a}$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, N-oxide, and $C_{3-8}$ cycloalkyl; ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

each $R^2$ is independently selected from the group consisting of hydrogen, $C_{1-6}$ alkyl, halogen, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, $C_{1-6}$ alkyl-$C_{1-6}$ alkoxy, CN, OH, $NR^{2a}R^{2b}$, $C(O)R^{2a}$, $C(O)OR^{2a}$, $C(O)NR^{2a}R^{2b}$, $SR^{2a}$, $S(O)R^{2a}$, $S(O)_2R^{2a}$, $C_{3-8}$ cycloalkyl, and $C_{3-8}$ heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;

alternatively, two $R^2$ groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 $R^{2c}$ groups;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are each independently selected from the group consisting of hydrogen and $C_{1\text{-}6}$ alkyl;

each $R^{3a}$ is independently halogen; and subscript n is an integer from 0 to 3,

or salts and isomers thereof.

34. The use of claim 33, wherein the nonsteroidal GRM compound comprising an octahydro fused azadecalin GRM is zavacorilant (which is ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone), which has the following structure:

